4: The RIVAWAR Trial and ACS Guidelines for LV Thrombus

The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest
22/04/2025 39 min Episodio 4
4: The RIVAWAR Trial and ACS Guidelines for LV Thrombus

Listen "4: The RIVAWAR Trial and ACS Guidelines for LV Thrombus"

Descargar episodio Ver en sitio original

Episode Synopsis

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial of rivaroxaban and a discussion of the newest Acute Coronary Syndrome Guidelines for left ventricular thrombus.

For more information:

Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association
Anticoagulation Forum Rapid Resources LV Thrombus
2025 ACC/AHA Guidelines
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots

More episodes of the podcast The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest

22: From Diagnosis to Transplant: A Heart Failure Patient’s Journey and the Pharmacists’ Impact Along the Way 16/12/2025
21: Breaking Down Celebrate and POLY-HF: Two Paths to Better Cardiac Care 02/12/2025
20: Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition 18/11/2025
19: Jazzed Up for American Heart Association 2025 in New Orleans 04/11/2025
18: The Adipokine Hypothesis and Inflammation: Explaining Pathogenesis and Guiding Treatment 21/10/2025
17: New Frontiers in Hypertension Care: Insights from the KARDIA-3 and Bax Hypertension Trials 07/10/2025
16: Deconstructing Meta-Analyses From ESC 2025 23/09/2025
15: ESC 2025 Highlights: Insights on ALONE-AF and AQUATIC Trials 09/09/2025
14: Sifting Through Discordant Data From ESC 2025 05/09/2025
13: From Guidelines to Action: Pharmacy’s Role in Hypertension Management 26/08/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA